Executive Board Partner

ABOUT SIERRA MEDICAL

Sierra Medical is advancing a clinically validated infrared spectral intelligence platform powered by explainable AI.

Our first deployment, AIR-DS Lung

, applies spectral pattern recognition to early lung cancer detection using standard laboratory infrastructure, delivering >90% accuracy in validation settings.

Over the past quarter, Sierra has entered a decisive expansion phase:

• IRB approval secured at a major U.S. cancer centre
• 13 sites in the RADICAL-REACT multi-centre validation study
• Successful launch of AIR-DS Version 1.0.0, our first clinically deployable diagnostic system
• Strengthened U.S. presence with new operations, clinical leadership, and advocacy partnerships
• Early discussions underway with U.S. and UK venture funds
• Growing demand from CLIA/ISO laboratories, health systems, and cancer networks

Sierra is now transitioning from clinical validation to structured commercialization.

As part of this phase, we are selectively expanding our Board.

THE OPPORTUNITY

Sierra Medical is forming a selective group of Executive Board Partners aligned with the commercialization and long-term expansion of its applied spectral intelligence platform.

This role is distinct from formal Board membership, yet operates in close strategic alignment with governance and ownership.

Executive Board Partners engage as senior operators and capital allocators who participate at a defined inflection point in the company’s growth.

Participation is curated and intentionally limited.

PLATFORM THESIS

Sierra’s immediate focus is healthcare deployment.

However, infrared spectroscopy combined with AI-driven spectral interpretation represents a foundational analytical capability, enabling real-time molecular fingerprinting and compositional analysis.

While healthcare remains the first regulated commercialization pathway, spectral intelligence has broader long-term optionality across:

• Advanced materials & aerospace composites

• Industrial chemical and energy analysis

• Agriculture & soil diagnostics

• Infrastructure & non-destructive testing

• Environmental and analytical screening

Executive Board Partners participate at a stage where the platform has validated in a high-barrier regulatory environment and is transitioning toward revenue.

ROLE OF EXECUTIVE BOARD PARTNERS

Executive Board Partners contribute through:

• Strategic dialogue around commercialization and scaling

• Cross-sector expansion insight

• Capital-aligned ownership participation

• Long-term platform perspective

• Visibility into governance-level decision making

Engagement is strategic and periodic, not operational.

COMPENSATION AND ALIGNEMENT

This is an equity-based Board role aligned with ownership participation in the company. Executive Board participation is structured for individuals who view strategic contribution and capital alignment as inherently linked. This is not a cash-compensated seat.

IDEAL PROFILE

We are seeking senior executives with 10+ years of leadership experience across one or more of the following domains:

• Healthcare systems, diagnostics, or regulated commercialization
• Deep technology or AI/ML infrastructure
• Advanced materials, aerospace, or energy innovation
• Industrial analytics or analytical instrumentation markets
• Enterprise software or data-driven technical platforms
• Executive leadership (CEO, COO, CTO, CCO, President, SVP Engineering
• Angel investing, venture participation, or principal capital allocation
• Prior board, governance, or strategic oversight experience

We are particularly interested in leaders who:

• Think in platform terms
• Have scaled technical infrastructure into complex markets
• Operate comfortably within regulated or compliance-driven environments
• Engage as long-term owners rather than external advisors

WHY THIS MOMENT MATTERS

AIR-DS is clinically deployable.

Multi-site validation is active.

Commercial infrastructure is in place.

The platform sits at a convergence point between scientific validation, regulatory progress, and market demand.

Board expansion at this stage offers participation during a defined commercialization inflection point.

EQUAL OPPORTUNITY COMMITMENT

Sierra Medical is committed to building a diverse, inclusive, and clinically representative Board. We welcome applicants from all backgrounds and do not discriminate on the basis of race, gender, ethnicity, disability, age, religion, or any protected characteristic.

We believe that diverse leadership perspectives—across clinical, commercial, and investment experience—strengthen our mission to make early, accessible disease detection a global reality.